Answers are grounded in this paper and cite their sources.
This work deals with the synthesis, characterization, cytotoxic evaluation, and initial DNA/HSA binding studies on cyclopalladated complexes of the type [PdBr(PheOMe-κ 2 C 2 ,N )(L)] {PheOMe-κ 2 C 2 ,N = orthometallated L -phenylalanine methyl ester; L = 2,6-lutidine ( 1 ), 1,3,5-Triaza-7-phosphaadamantane ( 2 )}. The molecular structure of compound 2 has been determined by single-crystal X-ray diffraction analysis. The stability of the complexes in DMSO has been evaluated via 1 H and 31 P NMR spectroscopy. The complexes have been tested against breast (MDA-MB-231), lung (A549), and ovarian (A2780) cancer cell lines, as well as non-tumor cell lines (MCF-10A – breast cell, and MRC-5 – lung cell). Compared to cisplatin, compound 1 exhibited superior cytotoxicity toward MDA-MB-231 cells (IC₅₀ = 6.04 μM) with minimal toxicity to normal cells (IC₅₀ > 50 μM). Morphological analyses and colony formation assays indicated that compound 1 compromised cell viability and inhibited proliferation in tumor cells. Cellular uptake studies indicated that 20.5% of the palladium corresponding to the initial amount available was detected in MDA-MB-231 cells after 48 h of treatment, which may suggest the accumulation/uptake of palladium by the cells. Compound 1 displayed a low DNA binding ability, which may suggest a distinct mechanism of action from that of cisplatin. In addition, complex 1 exhibited affinity for human serum albumin (HSA), which could facilitate its transport in biological systems. Overall, both complexes exhibited promising cytotoxicity with reduced toxicity toward noncancerous cells.
No takes yet. Share an insight, caveat, or question.
Badaró et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: